5/12/2009

GlaxoSmithKline obtained FDA clearance to launch a soluble formulation of Lamictal, a treatment for epilepsy and bipolar disorder. Lamictal ODT is expected to be on the market by July in doses of 25, 50, 100 and 200 milligrams, GSK said.

Full Story:
Forbes

Related Summaries